Virax Biolabs Group Limited (VRAX), a biotechnology firm specializing in immune response detection, has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies of its ViraxImmune™ technology.
The studies will examine immune profiling in patients with post-viral syndromes, starting with long COVID (post-acute sequelae of SARS-CoV-2).
Under the collaboration, Emory's Laboratory for Innovative Assay Development will manage patient recruitment, testing, and data analysis to generate clinical evidence supporting Virax's upcoming regulatory submissions and potential commercial launch. The initiative aligns with Virax's preparations for an FDA pre-submission meeting in September 2025 to define the intended use, regulatory pathway, and pivotal U.S. trial design for ViraxImmune™.
Virax CEO James Foster noted that the partnership strengthens the company's U.S. market strategy and addresses the urgent diagnostic needs of millions affected by long COVID and other post-viral syndromes. Dr. Wilbur A. Lam of Emory emphasized that immune profiling could improve diagnosis and inform treatment decisions for these underdiagnosed conditions.
ViraxImmune™ uses T cell testing to provide a more complete assessment of immune function than traditional antibody testing, offering potential applications in chronic and post-viral disease management.
Tuesday, VRAX closed at $0.6333, down 18.18%, and is trading after hours at $0.64, up 1.06%, on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.